Research programme: anti-CRTH2 monoclonal antibody - Amgen/Nxera Pharma
Alternative Names: Anti-CRTH2 monoclonal antibody research programme - Abgenix/Nxera Pharma; SOA 002Latest Information Update: 02 Apr 2024
At a glance
- Originator Amgen; Sosei
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Hypersensitivity; Inflammation